Close Menu

local coverage determination

The test, TruGraf, assesses differentially expressed genes in blood to rule out subclinical kidney transplant rejection in patients with stable renal function.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

The company reported $10.7 million in total revenues for the quarter and said test report volume for its DecisionDx-Melanoma test grew 27 percent.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractor Palmetto for the week of 8/22/2019.

The Medicare contractor has proposed to cover the non-invasive test for certain kidney and heart transplant patients.

The company is forging ahead with its Signatera liquid biopsy circulating tumor DNA minimal residual disease (MRD) test and Prospera transplant assessment assay.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors for Noridian for the week of 5/24/19.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors for Guardant Health, Natera, Transplant Genomics, and More for the week of 4/26/19.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors for Prospera, Noridian, CGS, and more for the week of 4/12/2019.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors. 

Pages

23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.

By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.

NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.

In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.